PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) tested three new features—regulatory roadmap and product development tracker, expedited scientific advice, and submission readiness meeting (SRM)—via submission data and surveys. Findings validate their role in tracking issues, cutting advice timelines, and strengthening marketing authorisation application (MAA) readiness, with tweaks needed for usability. For full details, see EMA’s announcement on new PRIME tools.
Flexible Trackers Spotlight Risks and Progress
The regulatory roadmap and product development tracker shifts from annual updates to flexible, issue-focused logs on EMA’s IRIS platform, capturing progress, risks, and interactions like kick-off meetings (KOMs) and scientific advice. In the pilot, 73 trackers covered 57 PRIME products, led by non-SME developers (72.6%) in advanced therapy medicinal products (ATMPs; 32), biologicals (27), and chemicals (14); 14 products saw iterative updates every 8.9 months on average. Regulators praised monitoring critical issues (83.3% agreement, 4.0/5 score) and KOM/SRM prep (81.8%), but developers flagged usability (45.5%) and SME burdens (23.3% submissions vs. 47% participation). This highlights transparency gains for assessors, with calls for guidance on updates, categorization, and feedback to amplify PRIME Scheme Evaluation insights.
Expedited Advice Slashes Response Times
Expedited scientific advice handles urgent, well-defined follow-ups from prior talks, delivering timely input outside standard timelines. Twelve requests for 10 products (41.6% orphan, 33% SME) spanned clinical, quality, and multidisciplinary topics; 91.7% qualified for fast tracks, with 81.8% completed in 50 days (vs. 79.6 standard), thanks to 6.5-day validation (vs. 24.9). Developers lauded adaptability (87.5%) and flexibility (75%), regulators backed criteria (100%) and Rapporteur roles (100%). Challenges like Scientific Advice Working Party (SAWP) cycles and no meetings suggest expanding to KOM/SRM issues, publishing timelines, and sub-SAWP options—proving time savings in the PRIME Scheme Evaluation.
SRMs Lock in MAA Readiness
Submission readiness meetings (SRMs), timed 9–12 months pre-MAA, unite developers, Rapporteurs, and EMA/EMRN experts to assess advice follow-through, data maturity, strategy, and accelerated assessment (AA) fit. Ten SRMs for varied products (30% ATMPs, 70% orphan) hit core topics (100% advice implementation, 90–100% dossier maturity, 80–83.3% AA), plus inspections (60%) and paediatric plans (40%); timing suited most (66.7–83.3%). Developers valued clarity (93.9%), expertise (83%), and risks (90%); regulators saw assessment prep gains (60–83.3%), though data timing lagged (20%). Of five MAAs, three got AA nods, signaling impact. Needs: flexible scheduling, expert inputs (e.g., PDCO), and tracker follow-ups.
PRIME Tools Reshape Access
PRIME Scheme Evaluation enhancements showcase EMA’s agile framework, streamlining the availability of drugs for unmet needs and speeding EU reimbursement under new laws. Trackers and 35.7-day expedited advice (vs. 56.9 standard) cut delays for mature post-MAA dossiers. SRMs tackle past PRIME timeline slips (>50%), as in pilot wins like Brinsupri and Vimkunya. Pairing with coordinators and digital tools boosts global predictability, cuts immature dossier risks, and fits agile regulatory trends.
